Isomorphic Labs released a technical report on IsoDDE, a proprietary drug‑discovery engine its developers say improves predictions of protein–drug interactions and antibody structures. The company touted precise modeling capabilities; independent scientists praised the advance but criticized the closed nature of the model and limited methodological transparency. Researchers cited parallels to DeepMind’s AlphaFold lineage but warned that withholding architectural details hinders reproducibility and slows wider scientific adoption. The debate underscores tension between proprietary competitive advantage and the open‑science norms in computational biology.